July 2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional £20 million in a Series B2 financing round.
Having demonstrated proof of efficacy in patients with refractory or unexplained chronic cough
i, NeRRe will now continue the clinical development of orvepitant in chronic cough caused by IPF, a rare type of interstitial lung disease
ii. A dominant symptom of this severe progressive fibrotic pulmonary disease, in a high proportion of these terminally ill patients, is an uncontrolled, persistent, and disabling cough.
NeRRe Therapeutics raises £20 million in a Series B2
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
NeRRe Therapeutics raises £20 million in a Series B2 financing round
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Queuing up to retake the stage, Pennsylvania Ballet has a new name
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Article content
I have been in Vancouver since March 18, visiting a bit-younger friend from University of Manitoba days who needed some help.
For me, this is a novel experience. I love the city’s hedges, but I am a “flatlander,” born in raised in the Netherlands, where in its entire 41,780 square kilometres the highest point is 323 metres above sea level, and the fifth-highest point is just 56 metres above sea level. And I have spent much of the past nearly 70 years on the Canadian Prairies or in the relatively flat country around Ottawa.
We apologize, but this video has failed to load.